News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InSite Vision (ISV) Completes DOUBle Phase 3 Clinical Study of AzaSite Plus™ and DexaSite™ for the Treatment of Blepharitis



3/25/2013 9:25:41 AM

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that the last patient has completed dosing and evaluation in the DOUBle Phase 3 clinical trial of AzaSite Plus™ and DexaSite™ for the treatment of blepharitis. There are more than 34 million blepharitis sufferers in the United States who currently have no FDA-approved drug therapies available to them. The DOUBle (Dual Ophthalmic agents Used in Blepharitis) study enrolled more than 900 patients with moderate-to-severe blepharitis in a four-arm trial designed to evaluate the efficacy and safety of both product candidates simultaneously. InSite Vision expects that top-line data from the DOUBle Phase 3 clinical trial will be available in the second quarter of 2013.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES